日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study

抗PD-1抗体penpulimab联合化疗治疗复发性或转移性鼻咽癌:一项随机、双盲3期研究

Huang, Shuang; Liu, Feng; Qu, Song; Chen, Lisha; Zhou, Ping; Qu, Shenhong; Ai, Xiaohong; Chen, Yong; Liu, Meilian; Wang, Rensheng; Chan, Kelvin Kw; Zhang, Peng; Hu, Chunhong; Wen, Jiyu; Zhang, Jian; Lin, Qin; Li, Xiaojiang; Gu, Kangsheng; Xiang, Li; Wang, Dongxia; Li, Jingao; Lin, Daren; Hu, Desheng; Ding, Jianwu; Wang, Siyang; Huang, Xiaoming; Wang, Lin; Jin, Feng; Pfister, David G; Mak, Milena Perez; Marchi, Pedro Rafael Martins de; Jiang, Yi; Yang, Haihua; Hu, Xiaoye; Liu, Tianrun; Wu, Dehua; Shreenivas, Aditya; Oliveira, Thiago Bueno de; Silva, Carlos Eduardo Baston; Alves, Gustavo Vasconcelos; Li, Xianming; Yao, Zhifang; Lu, Dongmei; Hu, Mingxiu; Wang, Zhongmin Maxwell; Li, Baiyong; Xia, Michelle; Chen, Xiaozhong; Hu, Chaosu; Xu, Tingting

IGF2BP3 promotes progression of head and neck cancers through the circHECTD2/hsa_miR_4310/7157-5p/Smad2 signaling axis in an m(6)A modification-dependent manner.

IGF2BP3 通过 circHECTD2/hsa_miR_4310/7157-5p/Smad2 信号轴以 m(6)A 修饰依赖的方式促进头颈癌的进展。

Wu Kainan, Chang Fen, Peng Tianjian, Wang Siyu, Sun Xiangkai, Wang Yin, Li Zinan, Duan Chengcheng, Li Jingao, Zhang Yijing, Su Tongdong, Li Wenming, Wei Dongmin, Cao Shengda, Liu Jun, Fang Jugao, Chen Long, Li Guojun, Gross Neil, Zhao Juan, Lei Dapeng

Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical Trial

卡瑞利珠单抗联合化疗治疗复发或转移性鼻咽癌的五年疗效:CAPTAIN-1st随机临床试验的二次分析

Huang, Yan; Sun, Dongchen; Zhou, Huaqiang; Zhou, Ting; Qu, Song; Li, Jingao; Hu, Chaosu; Xu, Mingjun; Li, Weidong; Shen, Liangfang; Wu, Hui; Lang, Jinyi; Hu, Guangyuan; Luo, Zhanxiong; Fu, Zhichao; Qu, Shenhong; Feng, Weineng; Chen, Xiaozhong; Lin, Shaojun; Xie, Bo; Li, Xiaojiang; Sun, Yan; Lin, Zhixiong; Lin, Qin; Lei, Feng; Long, Jianting; Hong, Jinsheng; Huang, Xiaoming; Zeng, Lingzhi; Wang, Peiguo; He, Xiaohui; Zhao, Shen; Chen, Gang; Zhang, Yaxiong; Zhao, Yuanyuan; Fang, Wenfeng; Huang, Chuanpei; Li, Xiaotong; Hong, Shaodong; Zhang, Li; Yang, Yunpeng

Anti-LAG-3 Antibody LBL-007 plus Tislelizumab and Chemotherapy as First-Line Therapy for Advanced Nasopharyngeal Carcinoma: A Multicenter Phase 2 Trial

抗LAG-3抗体LBL-007联合替雷利珠单抗和化疗作为晚期鼻咽癌一线治疗:一项多中心II期试验

Sun, Dongchen; Chen, Gang; Chen, Yu; Qu, Song; Liu, Lei; Yang, Kunyu; Li, Jingao; Chen, Lisha; Huang, Xiaoming; Zhu, Haisheng; Tang, Wenjun; Wang, Rensheng; Han, Yaqian; Hu, Desheng; Gao, Jin; Chen, Xiaozhong; Xiong, Hailin; Chen, Wu; Fan, Bin; Cai, Shengli; Kang, Xiaoqiang; Zhang, Li; Yang, Yunpeng

A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial.

针对晚期实体瘤的 B7H3 靶向抗体药物偶联物:一项 1/1b 期试验

Ma Yuxiang, Yang Yunpeng, Huang Yan, Fang Wenfeng, Xue Jinhui, Meng Xiangjiao, Fan Yun, Fu Siqing, Wu Lin, Zheng Yulong, Liu Jian, Liu Zhihua, Zhuang Wu, Rosen Seth, Qu Song, Li Bihui, Li Mingjun, Zhao Yanqiu, Yang Shujun, Ji Yinghua, Sommerhalder David, Luo Suxia, Yang Kunyu, Li Jingao, Lv Dongqing, Zhang Peng, Zhao Yuanyuan, Hong Shaodong, Zhang Yang, Zhao Shen, Chin Steve, Zhang Xian, Lian Wei, Cai Jiaqiang, Xue Tongtong, Zhang Li, Zhao Hongyun

Sequential vs Induction Plus Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma: A Randomized Clinical Trial

鼻咽癌序贯放化疗与诱导化疗联合同步放化疗的随机临床试验

Xue, Fen; Ou, Dan; Xie, Congying; Lin, Shaojun; Li, Jingao; Chen, Xiaozhong; Zhang, Fuzheng; Ying, Hongmei; Lu, Xueguan; Shen, Chunying; Xu, Tingting; Ou, Xiaomin; Li, Weiwei; Zhou, Xin; Du, Chengrun; Zhou, Changming; Hu, Chaosu; He, Xiayun

Bacterial Decolonization With Mupirocin Ointment for Acute Radiation Oral Mucositis Prevention: A Phase 3 Randomized Clinical Trial

使用莫匹罗星软膏进行细菌去定植以预防急性放射性口腔黏膜炎:一项3期随机临床试验

Liao, Zhaohui; Xiong, Xiaopeng; Zhao, Li; Zhang, Zipeng; Guan, Chunhong; Zhang, Lin; Zhong, Fangyan; Rao, Jun; Wang, Xunsong; Xiao, Yun; Gong, Xiaochang; Huang, Shao Hui; Li, Jingao; Lu, Tianzhu

MRPL21-PARP1 axis promotes cisplatin resistance in head and neck squamous cell carcinoma by inhibiting autophagy through the PI3K/AKT/mTOR signaling pathway.

MRPL21-PARP1 轴通过 PI3K/AKT/mTOR 信号通路抑制自噬,从而促进头颈部鳞状细胞癌的顺铂耐药性

Guan Rui, Li Ce, Jiao Ruijie, Li Jingao, Wei Ran, Feng Chen, Cao Shengda, Qian Ye, Fang Jugao, Liu Jun, Li Wenming, Wei Dongmin, Lei Dapeng

Targeting MED8 enhances sorafenib sensitivity in hepatocellular carcinoma by disrupting epithelial-mesenchymal transition mechanisms.

靶向 MED8 可通过破坏上皮-间质转化机制来增强肝细胞癌对索拉非尼的敏感性。

Li Ming, You Xiaoxiang, Yuan Tinghao, He Jun, Xu Zhiliang, Liang Siqin, Mao Lei, Jin Anan, Zhou Xinwen, Yi Bo, Li Jingao, Tu Qiang

Prognostic Significance of Circulating Immune Subset Counts in Nasopharyngeal Carcinoma

循环免疫亚群计数在鼻咽癌预后中的意义

Xie, Honghui; Zhang, Lin; Chen, Lizhi; Zhou, Wenchao; Zhang, Lijuan; Su, Yong; Li, Bocheng; Ding, Peng; Xiao, Yun; Lu, Tianzhu; Gong, Xiaochang; Li, Jingao